Compare RSG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RSG | ARGX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1B | 55.1B |
| IPO Year | 1998 | 2017 |
| Metric | RSG | ARGX |
|---|---|---|
| Price | $254.91 | $936.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 25 |
| Target Price | $257.42 | ★ $1,150.61 |
| AVG Volume (30 Days) | ★ 1.3M | 377.9K |
| Earning Date | 10-29-2026 | 10-22-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 5.55 | N/A |
| EPS | ★ 5.47 | N/A |
| Revenue | ★ $19,027,000,000.00 | N/A |
| Revenue This Year | $5.33 | $53.06 |
| Revenue Next Year | $4.99 | $23.03 |
| P/E Ratio | $46.73 | ★ $33.69 |
| Revenue Growth | ★ 3.31 | N/A |
| 52 Week Low | $196.41 | $661.85 |
| 52 Week High | $256.79 | $1,072.75 |
| Indicator | RSG | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 54.20 |
| Support Level | $206.53 | $934.19 |
| Resistance Level | N/A | $1,072.75 |
| Average True Range (ATR) | 4.70 | 25.28 |
| MACD | 0.40 | 6.39 |
| Stochastic Oscillator | 91.65 | 59.40 |
Republic Services Group is the second-largest waste management company by revenue and provides integrated waste management services to residential, commercial, and industrial customers. With 208 active landfills, 248 transfer stations, and 75 recycling centers, Republic Services has reached $16 billion in annual revenue, focusing on recycling and environmental solutions. The company reports in three segments based on the Western United States (Group 1), Eastern United States (Group 2), and Environmental Solutions across North America (Group 3). Eighty-nine percent of total revenue comes from recycling and waste, with the remaining 11% from Environmental Solutions.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.